Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:01 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia
NCT01286038 · H. Lee Moffitt Cancer Center and Research Institute · PHASE1 · terminated · last registry update 2022-11-07 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lack of efficacy” | – | Registry record, H. Lee Moffitt Cancer Center and Research Institute |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MPL within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-09-29Also stopped (withdrawn): Amgen, Romiplostim + Antithymocyte Globulin (NCT05323617)
- 2023-09-28Also stopped (withdrawn): Jiangsu HengRui Medicine Co., Ltd., Hetrombopag + Matching placebo (NCT05261646)
- 2023-09-15Also stopped (suspended): University of California, Davis, T-Vec (NCT04427306)
- 2023-09-13Results posted on the registry: National Heart, Lung, and Blood Institute (NHLBI), Eltrombopag (NCT04269889)
- 2023-07-27Results posted on the registry: Albert Einstein College of Medicine, Eltrombopag Olamine + Lenalidomide (NCT01772420)
- 2023-07-14Results posted on the registry: Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH, N-Plate / romiplostim (NCT02335268)
- 2023-06-18Phase 3 first posted: The First Affiliated Hospital of Soochow University, Decitabine + Granulocyte Colony-Stimulating Factor (NCT05907499)
- 2023-05-24Also stopped (withdrawn): European Organisation for Research and Treatment of Cancer - EORTC, Lomustine + Romiplostim (NCT04933942)
- 2023-03-23Results posted on the registry: M.D. Anderson Cancer Center, Eltrombopag (NCT01168921)
- 2023-02-01Results posted on the registry: M.D. Anderson Cancer Center, Eltrombopag Olamine (NCT01428635)
- 2022-12-30Results posted on the registry: Novartis Pharmaceuticals, Eltrombopag (ELT) (NCT01957176)
- 2022-12-16Phase 3 first posted: Novartis Pharmaceuticals, Ianalumab + Eltrombopag (NCT05653219)
- 2022-08-08Phase 3 first posted: AO GENERIUM, GNR-069 (NCT05492409)
- 2022-07-22Also stopped (terminated): Roswell Park Cancer Institute, eltrombopag olamine (NCT01550185)
- 2022-07-20Phase 3 first posted: The First Affiliated Hospital of Soochow University, Eltrombopag 25 MG Oral Tablet + Supportive care (NCT05466201)
- 2022-06-30Phase 3 first posted: Peking University People's Hospital, all-trans retinoic acid + Eltrombopag (NCT05438875)
- 2022-05-11Phase 3 first posted: Sobi, Inc., Avatrombopag Oral Tablet (NCT05369208)
- 2022-04-13Phase 3 first posted: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla, romiplostim plus dexamethasone + Dexamethasone (NCT05325593)
- 2022-03-02Phase 3 first posted: Jiangsu HengRui Medicine Co., Ltd., Hetrombopag + Matching placebo (NCT05261646)
- 2022-02-02Phase 3 first posted: AO GENERIUM, GNR-069 + Nplate (NCT05220878)
- 2021-12-09Also stopped (withdrawn): Ayman Saad, Avatrombopag (NCT04312789)
- 2021-11-24Results posted on the registry: Sobi, Inc., Avatrombopag + Placebo Oral Tablet (NCT03471078)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision